Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity.

Authors:
Hao Zhang
Hao Zhang
State Key Laboratory of Food Science and Technology
Nanchang Shi | China
Avijit Ray, PhD
Avijit Ray, PhD
AbbVie
Senior Scientist II
Immunology, Immuno-oncology, Autoimmunity and Inflammation, Immune tolerance
North Chicago, IL | United States
Nichole M Miller
Nichole M Miller
Blood Research Institute
United States
Danielle Hartwig
Danielle Hartwig
Medical College of Wisconsin
Kirkwood A Pritchard
Kirkwood A Pritchard
Medical College of Wisconsin
United States
Bonnie N Dittel
Bonnie N Dittel
Blood Research Institute

J Neurochem 2016 Feb 30;136(4):826-836. Epub 2015 Nov 30.

Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA.

Oxidative stress is thought to contribute to disease pathogenesis in the central nervous system (CNS) disease multiple sclerosis (MS). Myeloperoxidase (MPO), a potent peroxidase that generates toxic radicals and oxidants, is increased in the CNS during MS. However, the exact mechanism whereby MPO drives MS pathology is not known. We addressed this question by inhibiting MPO in mice with experimental autoimmune encephalomyelitis (EAE) using our non-toxic MPO inhibitor N-acetyl lysyltyrosylcysteine amide (KYC). We found that therapeutic administration of KYC for 5 days starting at the peak of disease significantly attenuated EAE disease severity, reduced myeloid cell numbers and permeability of the blood-brain barrier. These data indicate that inhibition of MPO by KYC restores blood-brain barrier integrity thereby limiting migration of myeloid cells into the CNS that drive EAE pathogenesis. In addition, these observations indicate that KYC may be an effective therapeutic agent for the treatment of MS. We propose that during experimental autoimmune encephalomyelitis (EAE) onset macrophages and neutrophils migrate into the CNS and upon activation release myeloperoxidase (MPO) that promotes disruption of the blood-brain barrier (BBB) and disease progression. KYC restores BBB function by inhibiting MPO activity and in so doing ameliorates disease progression.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jnc.13426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865458PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
February 2016
30 Reads
6 Citations
4.281 Impact Factor

Publication Analysis

Top Keywords

blood-brain barrier
16
autoimmune encephalomyelitis
12
experimental autoimmune
12
ameliorates disease
8
barrier integrity
8
encephalomyelitis eae
8
inhibiting mpo
8
disease progression
8
myeloperoxidase mpo
8
disease severity
8
restores blood-brain
8
kyc restores
8
mpo
7
disease
7
kyc
5
pathology addressed
4
cns activation
4
amide kyc
4
therapeutic administration
4
kyc therapeutic
4

References

(Supplied by CrossRef)

Similar Publications